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Abstract
Background: In children with malaria caused by Plasmodium falciparum, quinine administered
rectally may be easier to use and less painful than intramuscular or intravenous administration. The
objective of this review was to compare the effectiveness of intrarectal with intravenous or
intramuscular quinine for treating falciparum malaria.
Methods: All randomized and quasi-randomized controlled trials comparing intrarectal with
intramuscular or intravenous quinine for treating people with falciparum malaria located through
the following sources were included: Cochrane Infectious Diseases Group Specialized Register,
CENTRAL, MEDLINE, EMBASE, LILACS and CINAHL. Trial quality was assessed and data,
including adverse event data, were extracted. Dichotomous data were analysed using odds ratios
and continuous data using weighted mean difference.
Results: Eight randomized controlled trials (1,247 children) fulfilled the inclusion criteria. The
same principal investigator led seven of the trials. Five compared intrarectal with intravenous
quinine, and six compared intrarectal with intramuscular treatment. No statistically significant
difference was detected for death, parasite clearance by 48 hours and seven days, parasite and fever
clearance time, coma recovery time, duration of hospitalization and time before drinking began.
One trial (898 children) reported that intrarectal was less painful than intramuscular
administration.
Conclusion: No difference in the effect on parasites and clinical illness was detected for the use
of intrarectal quinine compared with other routes, but most trials were small. Pain during
application may be less with intrarectal quinine. Further larger trials, in patients with severe malaria
and in adults, are required before the intrarectal route could be recommended.
Background
Plasmodium falciparum malaria often causes serious illness,
particularly in Africa, South-East Asia and South America.
An estimated 200 million episodes of clinical malaria and
two million deaths occur in children under five years old
in Africa every year [1].
Uncomplicated malarial illness is usually treated with oral
drugs [2]. But as vomiting is a prominent feature in 30 to
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those who present to hospital with persistent vomiting
(regardless of severity of disease) or severe malaria require
other routes of administration, such as intravenous infu-
sion, intramuscular injection [7] or via the nasogastric
route. These different routes of administration require
trained staff and equipment, which may be in short sup-
ply in low- and middle-income countries.
Despite emerging resistance to commonly used drugs,
such as chloroquine and mefloquine, malaria parasites
remain sensitive to quinine in Africa [8,9]. In some parts
of South-East Asia, however, decreasing sensitivity to qui-
nine has been detected [10].
Although intramuscular injection is the most common
route of quinine administration used in low-and middle-
income countries, side effects have been reported [11]. In
some of these countries, it is the most common cause of
lower limb paralysis when administered mistakenly into
the sciatic nerve [12-14]. Other reported harmful effects of
intramuscular quinine injections are bacterial and viral
infections including tetanus [15], poliomyelitis [16,17]
and HIV [18,19]. An alternative to intravenous and intra-
muscular administration is, therefore, worth evaluating.
The intrarectal route has been used to give quinine [20].
Health workers with minimal training can give intrarectal
quinine to people who are either vomiting or comatose.
This provides early treatment of the illness and is one of
the strategies of the World Health Organization initiative
'Roll Back Malaria' http://www.who.int/malaria/home.
However, disadvantages of using the intrarectal route are
local irritation, diarrhoea and expulsion of the medica-
tion [21]. The likelihood of intrarectal irritation has been
reduced by the development of less acidic quinine gluco-
nate (in Quinimax®). People may also reject suppositories
and other intrarectal formulations in preference for the
intramuscular route because injections are perceived as a
more effective treatment, particularly in people who are
seriously ill [19].
This review summarizes existing trials that compare the
effectiveness and safety of intrarectal quinine with other
routes of administration in people with malaria caused by
P. falciparum.
The paper is based on a Cochrane review published in The
Cochrane Library 2005, Issue 1 [22].
Cochrane reviews are regularly updated as new evidence
emerges and in response to comments and criticisms, and
The Cochrane Library should be consulted for the most
recent version of the review. The conclusions presented
are the opinions of review authors and are not necessarily
shared by The Cochrane Collaboration.
Methods
The review's inclusion criteria were randomized and
quasi-randomized controlled trials comparing intrarectal
with intravenous or intramuscular quinine administra-
tion in patients with P. falciparum malaria (uncomplicated
or severe, and confirmed by a blood-slide examination).
Quinine could be used as a single therapy or in
combination.
The review's primary outcome measure was death, but
parasite clearance by 48 hours (number of participants
free of parasites by 48 hours), parasite clearance by day
seven (number of participants free of parasites by day
seven), parasite clearance time, fever clearance time, dura-
tion of hospitalization, coma recovery time, time lapse
before drinking or eating, and adverse events (serious
events that resulted in death, were life-threatening,
required hospitalization or resulted in discontinuation of
treatment, such as local pain, abscess formation, and
paralysis, mild or moderate adverse events, as classified or
defined by trial investigators, including vertigo and tinni-
tus) were also measured.
The search strategy aimed to identify all relevant trials
regardless of language or publication status (published,
unpublished, in press and in progress). The following
search terms were used: 'quinine', 'Quinimax®', 'cinchona
alkaloids', 'cinchona alkaloid', 'suppositories', 'supposi-
tory', 'rectal drug administration', 'administration, rectal',
'intrarectal', 'rectal', 'rectum' and 'malaria'. The following
databases were searched: Cochrane Infectious Diseases
Group Specialized Register (January 2005), Cochrane
Central Register of Controlled Trials (CENTRAL) pub-
lished in The Cochrane Library (Issue 4, 2004), MEDLINE
(1966 to January 2005), EMBASE (1974 to January 2005),
LILACS (1982 to January 2005) and CINAHL (1982 to
January 2005). The following conference proceedings
were also searched for relevant abstracts: The Third Multi-
lateral Initiative on Malaria Pan-African Conference, 18 to
22 November, 2002, Arusha, Tanzania, and the Third
European Congress on Tropical Medicine and Interna-
tional Health held in Lisbon, Portugal (September, 2002).
For unpublished or ongoing trials, individual researchers
working in the field and the pharmaceutical company
Sanofi-Synthélabo, which manufactured Quinimax® sup-
positories and intrarectal cream, were contacted. The ref-
erence lists of all studies identified by the above methods
were also checked.
The full reports for all potentially relevant trials were
retrieved and independently assessed for their eligibility.
For methodological quality, allocation sequence andPage 2 of 8
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be adequate, inadequate or unclear according to estab-
lished guidelines [23]. It was noted whether the partici-
pant, carer or outcome assessor was blind to the
intervention, and the inclusion of all randomized partici-
pants in the final analysis was considered to be adequate
if greater than 90%. Data were independently extracted
using standard forms, and trial authors were contacted
where additional unpublished data were required. Data
were analysed using Review Manager 4.2 software and
outcome measures were compared using odds ratios (OR)
for dichotomous data and weighted mean difference
(WMD) for continuous data, both with 95% confidence
intervals. The fixed-effect model was used for those with-
out statistically significant heterogeneity (see below).
Data were pooled on the same interventions (same route
of administration and drug regimen), where appropriate
and separate analyses for the intravenous and intramuscu-
lar control regimens were conducted. Adverse event data
were presented in a table, a meta-analysis and in a narra-
tive summary of the findings.
Heterogeneity was assessed by visually examining the for-
est plots (for overlapping confidence intervals and out-
liers) and using the chi-squared test for heterogeneity with
a 10% level of statistical significance. Because statistically
significant heterogeneity was detected for diarrhoea (an
adverse event), the DerSimonian and Laird random-
effects model was used to pool data for this outcome.
It was intended to use subgroup analyses or meta-regres-
sion to explore participant age (less than five years versus
five years or older), disease severity (uncomplicated ver-
sus severe) and different galenic quinine formulations
(solution, intrarectal cream or suppositories) as potential
sources of heterogeneity, but this was not possible
because of the uniformity of the age of participants (chil-
dren less than 15 years of age only) and the small number
of trials of people with severe disease and different galenic
formulations. It was intended to investigate publication
bias using funnel plots, but it was considered to be inap-
propriate in view of the small number of trials included.
Results
Description of studies
The search strategy identified 14 potentially relevant stud-
ies. Eight randomized controlled trials (involving 1,247
children) [20,24-30], one of which was quasi-randomized
[24], fulfilled the inclusion criteria. The same principal
investigator led seven of the trials. The trials recruited chil-
dren up to 15 years of age who were hospital in-patients
in Burkina Faso [26,30], Niger [20,24,25,27,29] or Togo
[28]. The criteria for inclusion in the trial were: the degree
of parasitaemia (>1,000 asexual P. falciparum stages/µl)
[20,24-27], vomiting [20,24,26,28] and severe malaria
[25,29]. All the trials had diarrhoea as an exclusion crite-
rion; some also used treatment with antimalarial drugs
before admission (seven trials), other documented causes
of fever (six trials) and forms of severe malaria (five trials).
Details on the number of participants, interventions and
outcomes investigated are listed in Table 1. Five trials (227
children) compared intrarectal with intravenously admin-
istered quinine. Four trials (179 children) compared intra-
rectal quinine administered for two to three days with
intravenous quinine administered for the same duration
[20,24-26], and one trial compared single doses of intra-
rectal quinine and intravenous quinine that were fol-
lowed by a three-day course of oral quinine [27].
Participants that had a two-day quinine course completed
a total of five days of treatment with oral chloroquine [26]
or quinine [27]. Six trials (1,122 children) compared
intrarectal with intramuscular quinine. Four trials com-
pared intrarectal and intramuscular quinine administered
for three days [20,24,28,30], one trial did not mention the
duration of treatment [29] and one trial gave a single dose
of intrarectal or intramuscular quinine followed by three
days of oral quinine [27].
Methodological quality of included studies
Four trials did not describe the method used to generate
the allocation sequence [20,26,28,30], three trials used
random-numbers tables [25,27,29] and one trial used
alternate allocation (quasi-randomization) [24]. None
used procedures to conceal allocation. The nature of the
interventions used did not allow blinding of participants
and carers, and none of the outcome assessors were
blinded. One trial excluded one participant (1.3%) from
the analysis [25]. Another trial [24] could only analyse the
parasite clearance time for 20 out of the 66 trial partici-
pants (30%) without providing a reason for the missing
participants. The other six trials did not report on any
exclusion or drop out of randomized participants. None
of the trials analysed data on an intention-to-treat basis.
None of the trials reviewed contained a power calculation
to determine the number of participants required to
achieve sufficient statistical power for a clinically mean-
ingful difference in effect of the different modes of admin-
istration to be detected.
Outcomes
Each trial reported on at least one of the review's pre-spec-
ified outcomes, but none reported on the time lapsed
before eating resumed. They also reported on other out-
comes not analysed in this systematic review: time for par-
asitaemia to fall by 50% (three trials), percentage of initial
parasitaemia after 24 hours (one trial) and 48 hours
(three trials), time before one could sit (one trial); time
before one could walk (one trial) and time for the body
temperature to fall below 37.5°C (one trial).Page 3 of 8
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quinine
There was no statistically significant difference between
the interventions for the number of deaths (100 partici-
pants, three trials) (Figure 1), parasite clearance at 48
hours (24 participants, one trial), parasite clearance time
(76 participants, one trial), fever clearance time (76 par-
ticipants, one trial) (Figure 2), duration of hospitalization
(76 participants, one trial) coma recovery time (76 partic-
ipants, one trial) and time until drinking began (76 par-
ticipants, one trial). Participants in two trials were
reported to have cleared their parasites by 48 hours
[26,28] while four trials reported that all participants had
cleared their parasites by day seven [20,21,24,26].
Two trials reported on adverse events and specifically
mentioned the absence of rectal irritation and diarrhoea
[25,26]. Barennes [26] also reported mucoid stools in four
children in the intrarectal group.
Effects of intrarectally versus intramuscularly administered 
quinine
There was no statistically significant difference between
the interventions in the number of deaths (1,110
participants, six trials) (Figure 1), parasite clearance at 48
hours (64 participants, one trial), fever clearance time
(1,022 participants, three trials) (Figure 2), duration of
hospitalization (58 participants, one trial) and coma
recovery time (58 participants, one trial). Four trials (154
participants) also reported that no deaths occurred. Para-
site clearance time was statistically significantly longer in
the participants treated with intrarectal quinine (mean
46.5 (standard deviation 22.0) hours) compared with
those treated with intramuscular quinine (27.4 (9.5)
Table 1: Trial participants, interventions and outcomes
Reference Participants Quinine: routes of administration 
and doses*
Outcomes
[20] 21 children aged 2 to 14 years in Niger (1) Intrarectal (8 mg/kg; gluconate cream)
(2) Intramuscular (4.7 mg/kg)
(3) Intravenous (4.7 mg/kg)
All 8 hourly for 3 days
Death, parasite clearance by day 7, 
adverse events
[24] 66 children aged 2 to 15 years in Niger (1) Intrarectal (11.8 mg/kg; given as 
Quinimax® diluted with water in a syringe)
(2) Intravenous (7.4 mg/kg)
(3) Intramuscular (7.4 mg/kg)
All 12 hourly for 3 days
Death, parasite clearance time, parasite 
clearance by day 7, fever clearance time, 
adverse events
[25] 77 children aged 2 to 15 years in Niger (1) Intrarectal (11.8 mg/kg once then 8.8 
mg/kg 8 hourly for 2 days; Quinimax® 
solution diluted in water via a syringe)
(2) Intravenous (4.7 mg/kg 8 hourly for 2 
days)
Death, parasite clearance time, fever 
clearance time, days in hospital, coma 
recovery time, time until drinking began, 
adverse events
[26] 48 children aged 2 to 15 years in Burkina 
Faso
(1) Intrarectal (bichlorhydrate diluted in a 
syringe)
(2) Intrarectal (cinchona alkaloid diluted in 
a syringe)
(3) Intravenous (bichlorhydrate)
(4) Intravenous (cinchona alkaloid)
All 8 mg/kg quinine 8 hourly for 2 days
Parasite clearance by 48 hours and 7 days
[27] 15 children aged 2 to 14 years in Niger (1) Intravenous (4.74 mg/kg)
(2) Intramuscular (4.74 mg/kg)
(3) Intrarectal (11.85 mg/kg)
All single dose
Death, parasite clearance by day 7, 
adverse events
[28] 64 children aged 0 to 15 years in Togo (1) Intrarectal (15 mg/kg: Quinimax® 
solution diluted in a syringe)
(2) Intramuscular (12.5 mg/kg) Both 12 
hourly for 3 days
Death, parasite clearance by day 2, 
adverse events
[29] 58 children aged 2 to 15 years in Niger (1) Intrarectal (17.9 mg/kg once, then 
11.75 mg/kg 12 hourly; Quinimax® diluted 
in a syringe
(2) Intramuscular (7.5 mg/kg 12 hourly)
Death, fever clearance time, duration of 
hospitalization, coma recovery time
[30] 898 children aged 1 to 15 in Burkina Faso (1) Intrarectal (20 mg/kg; Quinimax® 
diluted in a syringe)
(2) Intramuscular (12.5 mg/kg) Both 12 
hourly for 3 days
Death, fever clearance time, adverse 
events
*Quinine dose given as quinine basePage 4 of 8
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one trial) [24]. However, all ninety participants in three
trials [20,24,27] were reported to have cleared their para-
sites by day seven.
Data on adverse events were accessible for statistical anal-
ysis in three trials [23,27,29]. Assimadi [28] reported no
statistically significant difference between painful swell-
ing at the site of application (OR 0.13, 0.01 to 2.62, ran-
dom-effects model) and pain at the site of application
after administration (OR 0.1, 0.01 to 1.89, random-effects
model). Barennes [30] reported that pain during
administration occurred in four out of 450 participants
given intrarectal quinine and 412 out of 448 participants
given intramuscular quinine (OR 0.00, 0.00 to 0.00), with
a test result for overall effect of Z = 13.46 (P < 0.00001).
There was no statistically significant difference in the
number of participants with mild diarrhoea between the
groups (1,022 participants, three trials). The largest trial
[30] also documented adverse events affecting stool con-
sistency and content, pain in the rectum, effects on the rec-
Meta-analysis of effects of intrarectal, intravenous and intramuscular quinine on deathFigure 1
Meta-analysis of effects of intrarectal, intravenous and intramuscular quinine on death
Meta-analysis of effects of intrarectal, intravenous and intramuscular quinine on fever clearance time (hours)Figure 2
Meta-analysis of effects of intrarectal, intravenous and intramuscular quinine on fever clearance time (hours)
Study [reference] Intrarectal Control OR (fixed) Weight OR (fixed)
or sub-category n/N n/N 95% CI % 95% CI
Intrarectal versus intravenous quinine
 [20]       0/7                0/7        Not estimable
[25]       4/39               9/37 100.00     0.36 [0.10, 1.28]
[27]       0/5                0/5        Not estimable
Subtotal (95% CI) 51                 49 100.00     0.36 [0.10, 1.28]
Total events: 4 (Intrarectal), 9 (Control)
Test for heterogeneity: not applicable
Test for overall effect: Z = 1.59 (P = 0.11)
Intrarectal versus intramuscular quinine
[24]       0/55               0/11        Not estimable
 [20}       0/7                0/7        Not estimable
[27]       0/5                0/5        Not estimable
[29]       0/32               2/26 73.12     0.15 [0.01, 3.28]
[28]       0/32               0/32        Not estimable
[30]       3/450              1/448 26.88     3.00 [0.31, 28.95]
Subtotal (95% CI) 581                529 100.00     0.92 [0.21, 3.99]
Total events: 3 (Intrarectal), 3 (Control)
Test for heterogeneity: Chi? = 2.37, df = 1 (P = 0.12), I? = 57.8%
Test for overall effect: Z = 0.12 (P = 0.91)
0.001 0.01 0.1 1 10 100 1000
Favours intrarectal Favours control
Study [reference]  Intrarectal  Control  WMD (fixed)  Weight  WMD (fixed)
or sub-category N Mean (SD) N Mean (SD)  95% CI  %  95% CI
 Intrarectal versus intravenous quinine
[25]     39     39.00(5.20)          37     37.10(16.50) 100.00      1.90 [-3.66, 7.46]
Subtotal (95% CI)     39                          37 100.00      1.90 [-3.66, 7.46]
Test for heterogeneity: not applicable
Test for overall effect: Z = 0.67 (P = 0.50)
 Intrarectal versus intramuscular quinine
[24]     55     48.60(90.40)         11     35.90(16.30)   2.35     12.70 [-13.06, 38.46]
[29]     32     38.70(22.80)         26     38.60(22.60)  11.32      0.10 [-11.64, 11.84]
[30]    450     43.40(32.20)        448     40.80(32.80)  86.33      2.60 [-1.65, 6.85]
Subtotal (95% CI)    537                         485 100.00      2.55 [-1.40, 6.50]
Test for heterogeneity: Chi? = 0.76, df = 2 (P = 0.68), I? = 0%
Test for overall effect: Z = 1.27 (P = 0.20)
-100 -50  0  50  100
 Favours intrarectal  Favours controlPage 5 of 8
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administration (Table 2).
Three trials that reported on adverse events did not sepa-
rate the results for the intrarectal, intramuscular and intra-
venous groups [20,24,27]. They specifically commented
on the absence of rectal irritation (all three trials) and
diarrhoea [20,27]. Barennes [20] also observed slight pain
at the injection site in the intramuscular group.
Discussion
Seven out of the eight trials that met the inclusion criteria
consisted of less than 80 participants. This small number
of participants increased the probability of missing a clin-
ically important difference between groups. Only for the
outcomes of death, fever clearance time and mild diar-
rhoea (an adverse event) were there two or more trials
available for a meta-analysis. Only three of the trials doc-
umented the use of adequate randomization; adequate
randomization was particularly important because
blinding of participant and carer was not possible. This
has increased the risk of a selection bias. All but one trial
were conducted under the lead of one author, H.
Barennes. The only pharmaceutical company producing
an intrarectal quinine preparation, Quinimax®, sponsored
four of the trials [24,25,29,30].
There was no statistically significant difference between
intrarectal and parenteral quinine administration in terms
of death, course of P. falciparum malaria or diarrhoea.
Intrarectal administration also had the benefit of being
less painful.
Parasite clearance time was longer in participants given
quinine intrarectally as compared with intramuscular
treatment in one trial [24], but it was not different when
intrarectal administration was compared with intrave-
nous administration in another trial [25]. This may have
been because parasitaemia in the trial Barennes published
in 1995 [24] was three times higher at baseline in the
intrarectal group.
Statistically significant heterogeneity was observed when
analysing the mild diarrhoea adverse event outcome. This
may have been due to different definitions of diarrhoea,
which was only clearly defined in one trial [30], and the
large weight attributed in the meta-analysis to one small
trial in which two out of five participants in the control
group were affected [24]. Persistent pain at the injection
site due to inflammation with the recurrence of fever
seemed to be common with intramuscular injection and
is an adverse effect not observed with the intrarectal route.
This should be taken into consideration in the design of
future trials comparing the two modes of administration.
The occurrence of rectal mucosal ulcerations with intrarec-
tal administration and its significance should also be
assessed in all future trials. Adverse effects unique to the
methods of intramuscular administration (sciatic nerve
injury, infections with other viral and bacterial pathogens
through contaminated needles) or intravenous injection
(infections) are absent in intrarectal administration and
cannot be addressed in a trial setting where
administration is performed by trained personnel with
adequate supply of consumables.
All trials included in the review had only children as par-
ticipants, therefore, the results may not be applicable to
adults.
Only two small randomized controlled trials (135 chil-
dren) comparing intrarectal with intravenous [25] or
intramuscular treatment [29] had participants with severe
Table 2: Descriptive adverse event data from Barennes [30]
Adverse event Intrarectal (number affected/total 
number of patients, %)
Intramuscular (number affected/total 
number of patients, %)
Liquid stool (<3/day) 109/450 (24.2) 7/448 (1.5)
Mucoid stools 296/450 (65.7) 23/448 (5.10)
Blood in stool 20/450 (4.4) 3/448 (0.7)
Painful contractions 64/450 (14.2) No data
Inflammation at the injection site No data 358/448 (80)
Tenesmus 56/450 (12.4) No data
Number investigated by anoscopy with a single 
microulceration healing within 24 hours
4/259 (1.5) No data
Multiple microulcerations recovering by day 7 1/259 (0.4) No data
Difficulty in walking No data 67/448 (15)
Sciatic paresthesia No data 1/448 (0.2)
Fever recurrence due to inflammation or 
infection of the injection site
No data 30/448 (6.6)Page 6 of 8
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tiveness of intrarectal quinine in life-threatening forms of
malaria.
Conclusion
In a series of unconcealed trials from one research group,
intrarectal administration appeared to be superior to
intramuscular or intravenous administration in terms of
reduced pain during administration. No difference in the
effect on parasites and clinical illness was detected for the
use of intrarectal quinine compared with other routes, but
most trials were small. Thus, intrarectal application may
be superior for uncomplicated falciparum malaria in chil-
dren in cases in which administration of antimalarial
drugs by mouth is not possible. There is insufficient evi-
dence of the effectiveness of intrarectal quinine in severe
falciparum malaria in children.
Further large-scale concealed randomized controlled trials
are required to investigate intrarectally administered qui-
nine in severe falciparum malaria in children and in all
forms of falciparum malaria in adults. Further trials
should focus on adverse effects including short-term and
long-term effects on the rectal mucosa with intrarectal
administration. Trials investigating the use of intrarectal
quinine in the primary care setting, its role in preventing
hospital admission and early treatment in the commu-
nity, preventing complications associated with late pres-
entation at healthcare facilities, are also desirable.
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